Department of Genetics, Polish Mother's Memorial Hospital Research Institute, 93-338 Lodz, Poland.
R&D Department, Laboratory of Medical Genetics, GENOS Sp. z o.o., 91-033 Lodz, Poland.
Int J Mol Sci. 2023 Aug 24;24(17):13178. doi: 10.3390/ijms241713178.
Over a 46-month period, the objectives of the National Cancer Control Program (NCCP, pol. Narodowy Program Zwalczania Chorób Nowotworowych), coordinated by the Ministry of Health, were pursued by conducting genetic diagnostics on individuals at high risk of developing cancer. A total of 1097 individuals were enrolled in the study, leading to the identification of 128 cases of germline mutations. The implementation of the NCCP led to the identification of genetic mutations in 4.43% of the patients qualified for and screening tests, in 18.18% of those qualified for a comprehensive next-generation sequencing (NGS) panel in cases of breast and ovarian cancer, and in 17.36% of cases of colorectal and endometrial cancer. The research conducted allowed us to establish individualized preventive and therapeutic approaches for mutation carriers. However, the results prove that liberalizing the inclusion criteria for high-throughput diagnostics and the use of broad gene panels could significantly increase the percentage of detected carriers. This publication serves as a summary and discussion of the results obtained from the implementation of the NCCP as well as of the role of genetic consulting in personalized medicine.
在 46 个月的时间里,由卫生部协调的国家癌症控制计划(NCCP,pol. Narodowy Program Zwalczania Chorób Nowotworowych)通过对癌症高危个体进行基因诊断来实现其目标。共有 1097 人参与了该研究,发现了 128 例种系突变。NCCP 的实施导致在符合 和 筛查测试条件的患者中,有 4.43%的患者、在符合乳腺癌和卵巢癌综合下一代测序(NGS)面板条件的患者中,有 18.18%的患者、在结直肠癌和子宫内膜癌患者中,有 17.36%的患者发现了基因突变。该研究为突变携带者制定了个体化的预防和治疗方法。然而,结果表明,放宽高通量诊断的纳入标准并使用广泛的基因面板可以显著提高检测到的携带者的比例。本出版物总结和讨论了 NCCP 实施的结果,以及遗传咨询在个性化医学中的作用。